Department of Human Neuroscience, Sapienza University, Rome, Italy.
Eur J Pain. 2023 Jan;27(1):44-53. doi: 10.1002/ejp.2055. Epub 2022 Nov 23.
Neuropathic pain is an occasionally reported complication of coronavirus disease 2019 (COVID-19) that has received increased attention in scientific literature. In this systematic review and meta-analysis, we aimed to provide information on the frequency of neuropathic pain associated with COVID-19.
We systematically reviewed and analysed literature regarding neuropathic pain associated with COVID-19. Literature searches were conducted in PubMed, EMBASE and Cochrane Library databases. We considered prospective and retrospective studies published up until September 2022 (limitations included English language, full-text publications and studies including at least 10 patients). A random effects meta-analysis was performed and heterogeneity and publication bias were assessed.
We identified 149 studies. We included 17 studies in the systematic review, and six studies reporting the frequency of neuropathic pain in the acute/subacute phase of COVID-19 in the meta-analysis. The estimated frequency of neuropathic pain ranged between 0.4 and 25%. Forest plot analysis showed that the random effect overall frequency was 10% (95% confidence interval: 5%-15%), with a high level of heterogeneity (Chi = 104; Tau = 0.004; df = 5; I = 95%; test for overall effect: Z = 3.584; p < 0.0005). The overall risk of bias was moderate in all studies selected, particularly due to the poor description of neuropathic pain diagnostic criteria.
The pooled estimated frequency of neuropathic pain associated with COVID-19 should be considered with caution due to the high heterogeneity across studies and the poor description of the neuropathic pain diagnostic criteria applied.
Emerging evidence supports the development of neuropathic pain as a complication of COVID-19. However, longitudinal studies enrolling consecutive patients with COVID-19 that detail the diagnostic criteria for neuropathic pain are needed to better assess the frequency of this condition.
神经病理性疼痛是新型冠状病毒病 2019(COVID-19)的一种偶发并发症,在科学文献中受到了越来越多的关注。在本次系统评价和荟萃分析中,我们旨在提供与 COVID-19 相关的神经病理性疼痛的发生频率信息。
我们系统地回顾和分析了与 COVID-19 相关的神经病理性疼痛的文献。文献检索在 PubMed、EMBASE 和 Cochrane Library 数据库中进行。我们考虑了截至 2022 年 9 月发表的前瞻性和回顾性研究(限制条件包括英语语言、全文出版物以及至少包含 10 名患者的研究)。进行了随机效应荟萃分析,并评估了异质性和发表偏倚。
我们确定了 149 项研究。我们在系统评价中纳入了 17 项研究,在荟萃分析中纳入了 6 项报告 COVID-19 急性/亚急性期神经病理性疼痛发生率的研究。神经病理性疼痛的估计发生率在 0.4%至 25%之间。森林图分析显示,随机效应总体频率为 10%(95%置信区间:5%-15%),异质性水平较高(Chi ² = 104;Tau ² = 0.004;df = 5;I ² = 95%;总体效应检验:Z = 3.584;p < 0.0005)。所有入选研究的整体偏倚风险均为中度,特别是由于对神经病理性疼痛诊断标准的描述较差。
由于研究之间存在高度异质性,以及应用的神经病理性疼痛诊断标准描述较差,因此应谨慎考虑与 COVID-19 相关的神经病理性疼痛的汇总估计发生率。
新出现的证据支持将神经病理性疼痛作为 COVID-19 的一种并发症发展。然而,需要招募连续 COVID-19 患者的纵向研究,并详细描述神经病理性疼痛的诊断标准,以更好地评估这种情况的发生频率。